Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC

April 10th 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Trilaciclib Before Chemo Results in Real-World Reduction of Myelosuppressive Hematologic AEs in ES-SCLC

April 7th 2022

The use of trilaciclib prior to chemotherapy resulted in a 50% reduction in the percent of patients with extensive-stage small cell lung cancer who had grade 3 or higher myelosuppressive hematologic adverse effects in at least 1 blood cell lineage.

EMA Accepts Marketing Authorization Applications for Tislelizumab in Select ESCC and NSCLC

April 6th 2022

Marketing authorization applications seeking the approval of tislelizumab in patients with advanced or metastatic esophageal squamous cell carcinoma following previous systemic chemotherapy and in select patients with non–small cell lung cancer have been submitted to the European Medicines Agency.

Treatment Decisions in Non–Small Cell Lung Cancer

April 6th 2022

This publication highlights insights from expert stakeholders on the evolving therapeutic landscape of immunotherapy-based treatment regimens through a review of clinical scenarios of patients with non-small cell lung cancer.

Dr. Spigel on Potential Advancements in Targeted Therapy in NSCLC

April 5th 2022

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

Dr. Herbst on the Evolution of Targeted Therapies in NSCLC

April 5th 2022

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

Dr. Aggarwal on NGS in Molecular Testing in NSCLC

April 5th 2022

Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non–small cell lung cancer.

Dr. Kindsfather on the Evolution of Reflex Testing in Lung Cancer

April 4th 2022

Scott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.

Dr. Osarogiagbon on the Effects of the COVID-19 Pandemic on Lung Cancer Screening

March 31st 2022

Raymond U. Osarogiagbon, MD, FACP, discusses the long-term effects of the COVID-19 pandemic on lung cancer screenings.

Clinical Advancements of Targeted Antibody-Drug Conjugates in Breast and Lung Cancer

March 31st 2022

This article surveils key advancements in the role of antibody-drug conjugates in solid tumors by examining important clinical trial findings on targeting Trop-2 in breast and lung cancers.

Second-Line Eftilagimod Alpha Plus Pembrolizumab Shows Promising Activity in Metastatic Lung Cancer

March 31st 2022

The combination of eftilagimod alpha and pembrolizumab was found to produce an encouraging early overall survival rate of 73% at the 6-month landmark when used as second-line treatment in patients with PD-1/PD-L1–refractory, metastatic non–small cell lung cancer, according to data from part B of the phase 2 TACTI-002 trial.

Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLC

March 30th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

Tiragolumab Plus Atezolizumab/Chemo Misses PFS End Point in Extensive-Stage SCLC

March 30th 2022

The addition of the anti-TIGIT immunotherapy tiragolumab to atezolizumab plus carboplatin/etoposide failed to significantly improve progression-free survival over atezolizumab/chemotherapy alone when used in the frontline treatment of patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase 3 SKYSCRAPER-02 trial.

European Approval Sought for Neoadjuvant Nivolumab/Chemo in Resectable NSCLC

March 29th 2022

The European Medicines Agency has validated its type II variation application for nivolumab in combination with chemotherapy for use in the neoadjuvant treatment of patients with unresectable stage IB to IIIA non–small cell lung cancer.

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

March 29th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

Dr. Weksler on Addressing Disparities in Lung Cancer Care Delivery

March 26th 2022

Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.

Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung Cancer

March 26th 2022

Rabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.

Experts Survey Treatment Variations for Resectable NSCLC in Asian Populations

March 25th 2022

A panel of lung cancer experts from China, South Korea, and Japan share their insights on how they care for their patients with resectable EGFR-positive non–small cell lung cancer.

Dr. Asbun on the Importance of Multidisciplinary Approaches in Pancreatic Cancer

March 23rd 2022

Horacio J. Asbun, MD, discusses the importance of multidisciplinary approaches in pancreatic cancer.

Dr. Kotecha on MR-Guided Radiotherapy in Lung Cancer

March 23rd 2022

Rupesh Rajesh Kotecha, MD, discusses the use of magnetic resonance–guided radiotherapy in lung cancer.